A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation)

• Kangfu Anti-inflammatory Suppository (Drug): To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.

Primary outcomes

• The MCCormack scale scores of 240 subjects will be assessed [Change from base line on the 56 days after discontinuation]: assessment of the 70% reduction rate after treatment

Secondary outcomes

• The neutrophils of 240 participants will be assessed [Change from base line on the 28 days of medication and 56 days after discontinuation]: assessment of neutrophils returning to normal reference range
• The whole blood reduced viscosity from hemorheological tests of 240 participants will be assessed [Change from base line on the 28 days of medication and 56 days after discontinuation]: assessment of whole blood viscosity returning to normal reference range
• The plasma viscosity from hemorheological tests of 240 participants will be assessed [Change from base line on the 28 days of medication and 56 days after discontinuation]: assessment of the plasma viscosity returning to normal reference range
• The CRP of 240 participants will be assessed [Change from base line on the 28 days of medication and 56 days after discontinuation]: assessment of the CRP returning to normal reference range
• The volume of liquid on B-mode of 240 subjects will be assessed [Change from base line on the 28 days of medication and 56 days after discontinuation]: The changes of the volume of liquid on B-mode at different observation points before and after treatment will be assessed
• The white blood cells of 240 participants will be assessed [Change from base line on the 28 days of medication and 56 days after discontinuation]: assessment of the white blood returning to normal reference range
• The TCM syndrome scores of 240 subjects will be assessed [Change from base line on the 56 days after discontinuation]: assessment of the 70% reduction rate after treatment
• The VAS score of 240 subjects will be assessed [Change from base line on the 56 days after discontinuation]: assessment of the 70% reduction rate after treatment

Other outcomes

• Adverse events [Change from base line on the 28 days of medication and 56 days after discontinuation]: Observe the incidence of adverse events after medication
• Change of liver function [Change from base line on the 28 days of medication and 56 days after discontinuation]: To observe whether ALT and AST are within the normal reference range after medication
• Change of renal function [Change from base line on the 28 days of medication and 56 days after discontinuation]: To observe whether creatinine and urea nitrogen are within the normal reference range after treatment

Sex: Female, ages: 20 Years to 50 Years

Inclusion Criteria:

* (1) Women aged 20-50;
* (2) Sexual History ;
* (3) According to the diagnostic criteria of pelvic inflammatory diseases: according to the Diagnosis and Treatment Criteria of Pelvic Inflammatory Diseases (2014), the following specifications are as follows: A. uterine tenderness, or adnexal tenderness, or cervical lifting pain; B. axillary body temperature < 38 C. blood routine white blood cell count < 1.1 times the upper limit of normal value; D. blood routine neutrophil percentage < 90%;

All of the above four items are available. Exclusion Criteria:

* (4)McCormack:4-12;
* (5)TCM syndrome differentiation for damp-heat stagnation and Qi deficiency syndrome, A. lower abdominal pain; B. excessive amount of belt, yellow color, or odor; C. fatigue; D. tongue red, greasy fur, or with teeth marks, or blood stasis spots; the above four items are all available;
* (6)Those who agree to participate in this clinical trial and sign the informed consent form.

Exclusion Criteria:

* (1) Pregnant or recent (within 6 months) pregnant women, lactating women ;
* (2) To identify the pathogen as Neisseria gonorrhoeae;
* (3) Symptoms related to appendicitis, ectopic pregnancy, torsion or rupture of ovarian cyst pedicle, gastroenteritis, endometriosis, adenomyosis, trichomonal vaginitis, vulvovaginal candidiasis, bacterial vaginosis, etc.;
* (4)Those with critical condition or surgical indications, such as fallopian tube and ovary abscess, pelvic abscess, diffuse peritonitis, septicemia;
* (5)In patients with severe primary diseases such as heart, brain and hematopoietic system, ALT of liver function is higher than the upper limit of normal value, and Cr of renal function is higher than the upper limit of normal value;
* (6)One month before admission, Chinese and Western medicines were used to treat the disease, which made it difficult to judge the efficacy of drugs;
* (7)Anaphylactic constitution or persons known to be allergic to the medicines and their components used in this test ;
* (8)Researchers do not consider it appropriate to participate in this clinical trial;
* (9)Suspected or true history of alcohol and drug abuse, or other pathological changes or conditions that reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the working environment, unstable living environment, etc., are liable to lead to lost interviews, according to the judgement of researchers;
* (10)Participation in other clinical researchers within 3 months before admission;
* (11)Patients with suspected or confirmed quinolone contraindications, central or peripheral neuropathy, epilepsy, and depression

• Yanming Xie, Principal investigator, Institute of Basic Research in Clinical Medicine, China Academy of Chinese